Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention

Journal of the American College of Cardiology

Volumn 37, Issue 8, 2001, Pages 2059-2065

  Anderson, Keaven M ^a   Califf, Robert M ^b   Stone, Gregg W ^g   Neumann, Franz Josef ^e   Montalescot, Gilles ^f   Miller, Dave P ^d   Ferguson III, James J ^c   Willerson, James T ^c   Weisman, Harlan F ^a   Topol, Eric J ^h  

^a CENTOCOR INC   (United States)

^b DUKE UNIVERSITY   (United States)

^c TEXAS HEART INSTITUTE   (United States)

^d Lewin TAG Inc   (United States)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g LENOX HILL HOSPITAL   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR; HEPARIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVAL; THROMBUS;

ANTIBODIES, MONOCLONAL; ATHERECTOMY, CORONARY; CORONARY DISEASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS; STENTS; SURVIVAL ANALYSIS;

EID: 20244385431     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(01)01290-6     Document Type: Article

References (31)

1. Myonecrosis after revascularizarion procedures
2. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty: The EPIC Investigation
3. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularlzation
4. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
5. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction
6. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study)
7. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction
8. Clinical benefits of platelet glycoprotein IIb/IIIa blockade with coronary stenting in acute myocardial infarction
9. A prospective, randomized trial comparing primary balloon angioplasty with or without abciximab to primary stenting with or without abciximab in acute myocardial infarction - Primary end point analysis from the CADILLAC trial
10. Randomized trial of a GP IIb/IIIa platelet receptor blocker in refractory unstable angina
11. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
12. 3 blockade with percutaneous coronary intervention. EPIC investigator group: Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication
13. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: One year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade
14. Outcomes at one year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial
15. Phamacodynamics of chimeric glycoproteinc IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty
16. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention IMPACT-II Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II
17. Effects of platelet glycoprotein IIb/IIIa blockade with tlrofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosisInvestigators
18. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trialInvestigators
19. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for prevention of ischemic events with percutaneous coronary intervention, for the TARGET Investigators
20. IIb's are not IIb's
21. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
22. Abciximab reduces mortality in diabetics following percutaneous coronary intervention
23. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC investigators: Evaluation of 7E3 in Preventing Ischemic Complications
24. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications
25. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins
26. 7E3 monoclonal antibody directed agains the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1
27. Role of integrin alpha(v)beta3 in vascular biology
28. Increased expression of neutrophil and monocyte adhesion molecules LFA-1 and Mac-1 and their ligand ICAM-1 and VLA-4 throughout the acute phase of myocardial infarction: Possible implications for leukocyte aggregation and microvascular plugging
29. A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits
30. 3 and osteopontin expression during neointima formation